Short Interest in Longeveron Inc. (NASDAQ:LGVN) Decreases By 47.2%
by Doug Wharley · The Cerbat GemLongeveron Inc. (NASDAQ:LGVN – Get Free Report) was the recipient of a large decrease in short interest during the month of March. As of March 31st, there was short interest totaling 2,406,104 shares, a decrease of 47.2% from the March 15th total of 4,553,371 shares. Approximately 11.6% of the shares of the stock are short sold. Based on an average daily trading volume, of 3,391,138 shares, the days-to-cover ratio is currently 0.7 days.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Longeveron in a report on Thursday, January 22nd. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Longeveron has a consensus rating of “Hold” and a consensus price target of $3.00.
View Our Latest Stock Analysis on LGVN
Longeveron Trading Down 3.4%
Shares of LGVN stock traded down $0.04 during mid-day trading on Monday, hitting $1.12. 815,984 shares of the company’s stock were exchanged, compared to its average volume of 2,504,502. Longeveron has a fifty-two week low of $0.48 and a fifty-two week high of $1.83. The stock has a 50-day simple moving average of $0.77 and a two-hundred day simple moving average of $0.71. The company has a quick ratio of 1.33, a current ratio of 1.33 and a debt-to-equity ratio of 0.03. The stock has a market cap of $26.06 million, a price-to-earnings ratio of -0.87 and a beta of -0.18.
Longeveron (NASDAQ:LGVN – Get Free Report) last posted its quarterly earnings data on Tuesday, March 17th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.42) by $0.20. Longeveron had a negative return on equity of 199.79% and a negative net margin of 1,893.58%.The business had revenue of $0.37 million for the quarter, compared to analysts’ expectations of $0.11 million. Equities analysts expect that Longeveron will post -3.69 EPS for the current fiscal year.
Institutional Investors Weigh In On Longeveron
An institutional investor recently bought a new position in Longeveron stock. XTX Topco Ltd acquired a new position in shares of Longeveron Inc. (NASDAQ:LGVN – Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 48,003 shares of the company’s stock, valued at approximately $62,000. XTX Topco Ltd owned about 0.32% of Longeveron as of its most recent SEC filing. Institutional investors and hedge funds own 10.01% of the company’s stock.
Longeveron Company Profile
Longeveron Inc is a clinical-stage biotechnology company focused on the development and commercialization of allogeneic cellular therapies designed to address aging-related and inflammatory conditions. The company’s primary therapeutic candidate, Lomecel-B, is an off-the-shelf mesenchymal stem cell product derived from bone marrow. Through its proprietary manufacturing process, Longeveron aims to produce a consistent, scalable cell therapy platform with potential applications in multiple disease areas.
Longeveron’s pipeline encompasses several ongoing and completed clinical studies.